Comparative Pharmacology
Head-to-head clinical analysis: EYSUVIS versus PREDNISOLONE EYE DROPS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EYSUVIS versus PREDNISOLONE EYE DROPS.
EYSUVIS vs Prednisolone Eye Drops
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Eysuvis (loteprednol etabonate ophthalmic suspension) is a corticosteroid that works by inducing phospholipase A2 inhibitory proteins, collectively called lipocortins, which inhibit the release of arachidonic acid and subsequent synthesis of prostaglandins and leukotrienes, thereby reducing inflammation.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression and suppressing inflammatory mediators such as prostaglandins and leukotrienes.
1 drop in each eye twice daily (approximately 12 hours apart) for 4 weeks.
Instill 1-2 drops into the conjunctival sac of the affected eye(s) four times daily. In severe cases, dosing may be initiated with 1-2 drops every 1-2 hours and tapered upon improvement.
None Documented
None Documented
Approximately 2-4 hours for loteprednol etabonate; clinical effect correlates with dosing interval (e.g., 4 times daily).
Plasma: 2-4 hours; tissue effects persist 18-36 hours. Clinically, duration of adrenal suppression may exceed plasma half-life.
Primarily renal (90-95% as unchanged drug and metabolites); minor biliary/fecal (<5%).
Renal (primarily as metabolites): ~70% after oral dose; unchanged drug: <20%. Biliary/fecal: minor.
Category C
Category A/B
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid